![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 2
2022
Mirza, Mansoor Raza; Lindahl, Gabriel; Mahner, Sven; Redondo, Andres; Fabbro, Michel; Rimel, Bobbie J.; Herrstedt, Jorn; Oza, Amit M.; Canzler, Ulrich; Berek, Jonathan S.; Gonzalez-Martin, Antonio; Follana, Phillipe; Lord, Rosemary; Azodi, Masoud; Estenson, Kasey; Wang, Zebin; Li, Yong; Gupta, Divya; Matulonis, Ursula und Feng, Bin
(2022):
Ad hoc Analysis of the Phase III ENGOT-OV16/NOVA Study: Niraparib Efficacy in Germline BRCA Wild-type Recurrent Ovarian Cancer with Homologous Recombination Repair Defects.
In: Cancer Research Communications, Bd. 2, Nr. 11: S. 1436-1444
2020
Harter, Philipp; Pautier, Patricia; Nieuwenhuysen, Els van; Reuss, Alexander; Redondo, Andres; Lindemann, Kristina; Kurzeder, Christian; Petru, Edgar; Heitz, Florian; Sehouli, Jalid; Degregorio, Nikolaus; Wimberger, Pauline; Burges, Alexander; Cron, Nadin; Ledermann, Jonathan; Lorusso, Domenica; Paoletti, Xavier und Marme, Frederik
(2020):
Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer - a randomized phase III trial (AGO-OVAR 2.29/ENGOT-ov34).
In: International Journal of Gynecological Cancer, Bd. 30, Nr. 12: S. 1997-2001